Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for cash ...

In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh ...

World Bipolar Day, which occurred 30 th March 2026, raises awareness and encourages better understanding of bipolar disorder, ...

Biogen is offering $41 per share for Apellis, with another $4 on offer if C3 inhibitor Syfovre (pegcetacoplan), approved by ...

Centessa Pharma is heading for an acquisition by Eli Lilly, which has offered $6.3 billion for the company, with another $1.5 ...

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

AstraZeneca's Alexion unit is planning to file a new, long-acting follow-up to its Strensiq therapy for ultra-rare disease ...

Private equity firm Blackstone has said that its latest life sciences fund – BXLS VI – has closed with a total of $6.3 ...

Central to that evolution is the transformation of care delivery. As published in Digital Engineering, digital transformation ...

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7 billion bid to acquire Terns Pharma. The Financial Times first reported that talks between the ...

Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple sclerosis (RMS), and is now being prepared for regulatory filings. The ...